Allogeneic hematopoietic stem cell transplantation - Yesterday, today, and tomorrow

Experimental Hematology

Volumn 31, Issue 1, 2003, Pages 1-10

  Storb, Rainer ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER THERAPY; CLINICAL TRIAL; DONOR; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MEDICAL RESEARCH; PRIORITY JOURNAL; REVIEW; SIBLING; TREATMENT INDICATION;

ANIMALS; CATTLE; CLINICAL TRIALS; DOGS; FORECASTING; GRAFT VS HOST DISEASE; GUINEA PIGS; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HOST VS GRAFT REACTION; HUMANS; MICE; PRIMATES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0037240708     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(02)01020-2     Document Type: Review

References (102)

1. Jacobson L.O., Marks E.K., Robson M.J., Gaston E.O., Zirkle R.E. Effect of spleen protection on mortality following x-irradiation. J Lab Clin Med. 34:1949;1538-1543.
2. Lorenz E., Uphoff D., Reid T.R., Shelton E. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J Natl Cancer Inst. 12:1951;197-201.
3. Jacobson L.O., Simmons E.L., Marks E.K., Gaston E.O., Robson M.J., Eldredge J.H. Further studies on recovery from radiation injury. J Lab Clin Med. 37:1951;683-697.
4. Jacobson L.O. Evidence for a humoral factor (or factors) concerned in recovery from radiation injury. a review Cancer Res. 12:1952;315-325.
5. Main J.M., Prehn R.T. Successful skin homografts after the administration of high dosage X radiation and homologous bone marrow. J Natl Cancer Inst. 15:1955;1023-1029.
6. Owen R.D. Immunogenetic consequences between vascular anastomoses between bovine twins. Science. 102:1945;400-402.
7. Nowell P.C., Cole L.J., Habermeyer J.G., Roan P.L. Growth and continued function of rat marrow cells in x-radiated mice. Cancer Res. 16:1956;258-261.
8. Ford C.E., Hamerton J.L., Barnes D.W.H., Loutit J.F. Cytological identification of radiation-chimaeras. Nature. 177:1956;452-454.
9. Trentin J.J. Mortality and skin transplantability in x-irradiated mice receiving isologous or heterologous bone marrow. Proc Soc Exp Biol Med. 92:1956;688-693.
10. Vos O., Davids J.A.G., Weyzen W.W.H., van Bekkum D.W. Evidence for cellular hypothesis in radiation protection by bone marrow cells. Acta Physiologica et Pharmacologica Neerlandica. 4:1956;482-486.
11. Lindsley D.L., Odell T.T., Tausche F.G. Implantation of functional erythropoietic elements following total-body irradiation. Proc Soc Exp Biol Med. 90:1955;512-515.
12. Makinodan T. Circulating rat cells in lethally irradiated mice protected with rat bone marrow. Proc Soc Exp Biol Med. 92:1956;174-179.
13. Bortin M.M. A compendium of reported human bone marrow transplants. Transplantation. 9:1970;571-587.
14. van Bekkum D.W., de Vries M.J. Radiation chimaeras. 1967;Logos Press Limited, London.
15. Storb R., Thomas E.D. Graft-vs-host disease in dog and man. The Seattle Experience Möller G. Immunological Reviews No.88. 1985;215-238 Munksgaard, Copenhagen.
16. nd ed:1999;1-11 Blackwell Science, Boston.
17. Morell V. The origin of dogs. running with the wolves Science. 276:1997;1647-1648.
18. Thomas E.D., Storb R., Clift R.A.et al. Bone-marrow transplantation. N Engl J Med. 292:1975;832-843., 895-902.
19. Uphoff D.E. Alteration of homograft reaction by A-methopterin in lethally irradiated mice treated with homologous marrow. Proc Soc Exp Biol Med. 99:1958;651-653.
20. Lochte Jr HL, Levy AS, Guenther DM, Thomas ED, Ferrebee JW. Prevention of delayed foreign marrow reaction in lethally irradiated mice by early administration of methotrexate. Nature. 196:1962;1110-1111.
21. Storb R., Epstein R.B., Graham T.C., Thomas E.D. Methotrexate regimens for control of graft-vs-host disease in dogs with allogeneic marrow grafts. Transplantation. 9:1970;240-246.
22. Storb R., Deeg H.J., Farewell V.et al. Marrow transplantation for severe aplastic anemia. Methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-vs-host disease Blood. 68:1986;119-125.
23. Storb R., Deeg H.J., Whitehead J.et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft vs host disease after marrow transplantation for leukemia. N Engl J Med. 314:1986;729-735.
24. Storb R., Raff R.F., Appelbaum F.R.et al. FK506 and methotrexate prevent graft-vs-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated DLA-nonidentical donors. Transplantation. 56:1993;800-807.
25. Nash R.A., Antin J.H., Karanes C.et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-vs-host disease after marrow transplantation from unrelated donors. Blood. 96:2000;2062-2068.
26. Yu C., Seidel K., Nash R.A.et al. Synergism between mycophenolate mofetil and cyclosporine in preventing graft-vs-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts. Blood. 91:1998;2581-2587.
27. Martin P.J., Hansen J.A., Buckner C.D.et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood. 66:1985;664-672.
28. Marmont A.M., Horowitz M.M., Gale R.P.et al. T-cell depletion of HLA-identical transplants in leukemia. Blood. 78:1991;2120-2130.
29. Goldman J.M., Gale R.P., Horowitz M.M.et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. increased risk of relapse associated with T-cell depletion Ann Intern Med. 108:1988;806-814.
30. Aversa F., Terenzi A., Carotti A.et al. Improved outcome with T-cell-depleted bone marrow transplantation for acute leukemia. J Clin Oncol. 17:1999;1545-1550.
31. Papadopoulos E.B., Carabasi M.H., Castro-Malaspina H.et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia. freedom from relapse in the absence of graft-vs-host disease Blood. 91:1998;1083-1090.
32. Mackinnon S., Papadopoulos E.B., Carabasi M.H.et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation. separation of graft-vs-leukemia responses from graft-vs-host disease Blood. 86:1995;1261-1268.
33. Thomas E.D., Buckner C.D., Clift R.A.et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med. 301:1979;597-599.
34. Thomas E.D., Sanders J.E., Flournoy N.et al. Marrow transplantation for patients with acute lymphoblastic leukemia in remission. Blood. 54:1979;468-476.
35. Thomas E.D., Clift R.A., Fefer A.et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med. 1 04:1986;155-163.
36. Forman S.J., Spruce W.E., Farbstein M.J.et al. Bone marrow ablation followed by allogeneic marrow grafting during first complete remission of acute nonlymphocytic leukemia. Blood. 61:1983;439-442.
37. Goldman J.M., Apperley J.F., Jones L.et al. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med. 314:1986;202-207.
38. Clift R.A., Buckner C.D., Thomas E.D.et al. Marrow transplantation for chronic myeloid leukemia. a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide Blood. 84:1994;2036-2043.
39. Clift R.A., Radich J., Appelbaum F.R.et al. Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogeneic marrow transplants during chronic phase of chronic myeloid leukemia. Blood. 94:1999;3960-3962. [correspondence].
40. Santos G.W., Tutschka P.J., Brookmeyer R.et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 309:1983;1347-1353.
41. Storb R., Etzioni R., Anasetti C.et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood. 84:1994;941-949.
42. Storb R., Blume K.G., O'Donnell M.R.et al. Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations. the experience in four centers Biol Blood Marrow Transplant. 7:2001;39-44.
43. Lucarelli G., Galimberti M., Polchi P.et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med. 322:1990;417-421.
44. Lucarelli G., Galimberti M., Polchi P.et al. Marrow transplantation in patients with Thalassemia responsive to iron chelation therapy. N Engl J Med. 329:1993;840-844.
45. Walters M.C., Patience M., Leisenring W.et al. Bone marrow transplantation for sickle cell disease. N Engl J Med. 335:1996;369-376.
46. nd ed:1999;915-928 Blackwell Science, Boston.
47. Hansen J.A., Gooley T.A., Martin P.J.et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 338:1998;962-968.
48. Bensinger W.I., Martin P.J., Storer B.et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 344:2001;175-181.
49. Ringden O., Remberger M., Runde V.et al. Peripheral blood stem cell transplantation from unrelated donors. a comparison with marrow transplantation Blood. 94:1999;455-464.
50. Schmitz N., Bacigalupo A., Hasenclever D.et al. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia. first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation Bone Marrow Transplant. 21:1998;995-1003.
51. Couban S., Simpson D.R., Barnett M.J.et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood. 100:2002;1525-1531.
52. Schmitz N., Beksac M., Hasenclever D.et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood. 100:2002;761-767.
53. Gluckman E., Rocha V., Boyer-Chammard A.et al. Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med. 337:1997;373-381.
54. Kurtzberg J., Laughlin M., Graham M.L.et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med. 335:1996;157-166.
55. Rubinstein P., Carrier C., Scaradavou A.et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med. 339:1998;1565-1577.
56. Wagner J.E., Barker J.N., Defor T.E.et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases. influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival Blood. 100:2002;1611-1618.
57. Aversa F., Tabilio A., Velardi A.et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 339:1998;1186-1193.
58. Burchenal J.H., Oettgen H.F., Holmberg E.A.D., Hemphill S.C., Reppert J.A. Effect of total body irradiation on the transplantability of mouse leukemias. Cancer Res. 20:1960;425.
59. Barnes D.W.H., Corp M.J., Loutit J.F., Neal F.E. Treatment of murine leukaemia with x-rays and homologous bone marrow. Preliminary communication. Br Med J. 2:1956;626-627.
60. Barnes D.W.H., Loutit J.F. Treatment of murine leukaemia with x-rays and homologous bone marrow. II Br J Haematol. 3:1957;241-252.
61. Mathé G., Amiel J.L., Schwarzenberg L., Catton A., Schneider M. Adoptive immunotherapy of acute leukemia. Experimental and clinical results Cancer Res. 25:1965;1525-1531.
62. Weiden P.L., Sullivan K.M., Flournoy N., Storb R., Thomas E.D., the Seattle Marrow Transplant Team Antileukemic effect of chronic graft-vs-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 304:1981;1529-1533.
63. Weiden P.L., Flournoy N., Thomas E.D.et al. Antileukemic effect of graft-vs-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 300:1979;1068-1073.
64. Horowitz M.M., Gale R.P., Sondel P.M.et al. Graft-vs-leukemia reactions after bone marrow transplantation. Blood. 75:1990;555-562.
65. Sullivan K.M., Weiden P.L., Storb R.et al. Influence of acute and chronic graft-vs-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 73:1989;1720-1728.
66. Gale R.P., Marmont A., Horowitz M., Bortin M.M. T cell depletion to prevent GvHD. Preliminary univariate analyses of the IBMTR Bone Marrow Transplant. 4(suppl 2):1989;121.
67. Gale R.P., Horowitz M.M., Ash R.C.et al. Identical twin bone marrow transplants for leukemia. Ann Intern Med. 120:1994;646-652.
68. Goulmy E. Human minor histocompatibility antigens. new concepts for marrow transplantation and adoptive immunotherapy (Review) Immunol Rev. 157:1997;125-140.
69. nd ed:1999;327-341 Blackwell Science, Boston.
70. Kolb H.J., Mittermüller J., Clemm C.H.et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 76:1990;2462-2465.
71. Kolb H.J., Schattenberg A., Goldman J.M.et al. Graft-vs-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood. 86:1995;2041-2050.
72. Slavin S., Naparstek E., Nagler A., Ackerstein A., Kapelushnik J., Or R. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol. 23:1995;1553-1562.
73. Collins Jr RH, Goldstein S, Giralt S, et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant. 26:2000;511-516.
74. st ed:2000;111-137 Martin Dunitz Ltd, London, UK.
75. Slavin S., Nagler A., Naparstek E.et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 91:1998;756-763.
76. Giralt S., Estey E., Albitar M.et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy. harnessing graft-vs-leukemia without myeloablative therapy Blood. 89:1997;4531-4536.
77. McSweeney P., Niederwieser D., Shizuru J.et al. Outpatient allografting with minimally myelosuppressive, immunosuppressive conditioning of low-dose TBI and postgrafting cyclosporine (CSP) and mycophenolate mofetil (MMF). Blood. 94(suppl 1):1999;393a., #1742 [abstract].
78. Feinstein L., Sandmaier B., Maloney D.et al. Nonmyeloablative hematopoietic cell transplantation. replacing high-dose cytotoxic therapy by the graft-vs-tumor effect Ann NY Acad Sci. 938:2001;328-339.
79. McSweeney P.A., Niederwieser D., Shizuru J.A.et al. Hematopoietic cell transplantation in older patients with hematologic malignancies. replacing high-dose cytotoxic therapy with graft-vs-tumor effects Blood. 97:2001;3390-3400.
80. Khouri I.F., Keating M., Körbling M.et al. Transplant-lite. induction of graft-vs-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies J Clin Oncol. 16:1998;2817-2824.
81. nd ed:1999;287-295 Blackwell Science, Boston.
82. Carella A.M., Champlin R., Slavin S., McSweeney P., Storb R. Mini-allografts. ongoing trials in humans (Editorial) Bone Marrow Transplant. 25:2000;345-350.
83. Spitzer T.R., McAfee S., Sackstein R.et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant. 6:2000;309-320.
84. Sykes M., Preffer F., McAfee S.et al. Mixed lymphohaemopoietic chimerism and graft-vs-lymphoma effects after nonmyeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet. 353:1999;1755-1759.
85. Childs R., Chernoff A., Contentin N.et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 343:2000;750-758.
86. Childs R., Clave E., Contentin N.et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation. full donor T-cell chimerism precedes alloimmune responses Blood. 94:1999;3234-3241.
87. Storb R., Yu C., Wagner J.L.et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 89:1997;3048-3054.
88. Storb R., Yu C., Barnett T.et al. Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. Blood. 94:1999;1131-1136.
89. Storb R., Yu C., Zaucha J.M.et al. Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4Ig, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant. Blood. 94:1999;2523-2529.
90. Yu C., Storb R., Mathey B.et al. DLA-identical bone marrow grafts after low-dose total body irradiation. Effects of high-dose corticosteroids and cyclosporine on engraftment Blood. 86:1995;4376-4381.
91. Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. In press.
92. Feinstein LC, Sandmaier BM, Hegenbart U, et al. Nonmyeloablative allografting from HLA-identical sibling donors for treatment of acute myeloid leukemia in first complete remission. Br J Haematol. In press.
93. Georges G.E., Storb R., Thompson J.D.et al. Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantation. Blood. 95:2000;3262-3269.
94. Woolfrey A.E., Nash R.A., Sanders J.E., Ochs H.D., Thomson B., Storb R. A nonmyeloablative regimen for induction of multi-lineage hematopoietic mixed donor-host chimerism in nonmalignant disorders. Blood. 98(Part 1):2000;784a., #3390 [abstract].
95. 213Bismuth-Anti-TCRab radioimmunoconjugate Blood. 98:2001;168a., #710.
96. Maris M, Storb R. The transplantation of hematopoietic stem cells after nonmyeloablative conditioning. Immunologic Research. In press.
97. Maloney D.G., Sahebi F., Stockerl-Goldstein K.E.et al. Combining an allogeneic graft-vs-myeloma effect with high-dose autologous stem cell rescue in the treatment of multiple myeloma. Blood. 98(Part 1):2001;434a. [abstract].
98. Sandmaier B.M., Maloney D.G., Gooley T.et al. Nonmyeloablative hematopoietic stem cell transplants (HSCT) from HLA-matched related donors for patients with hematologic malignancies. clinical results of a TBI-based conditioning regimen Blood. 98(Part 1):2001;742a. [abstract].
99. Maris M., Niederwieser D., Sandmaier B.et al. Nonmyeloablative hematopoietic stem cell transplants (HSCT) using 10/10 HLA antigen matched unrelated donors (URDs) for patients with advanced hematologic malignancies ineligible for conventional HSCT. Blood. 98(Part 1):2001;858a., #3563 [abstract].
100. Weissinger F., Sandmaier B.M., Maloney D.G., Bensinger W.I., Gooley T., Storb R. Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood. 98:2001;3584-3588.
101. Junghanss C., Marr K.A., Carter R.A.et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation, a matched control study. Biol Blood Marrow Transplant. 8:2002;512-520.
102. Junghanss C., Boeckh M., Carter R.A.et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. Blood. 99:2002;1978-1985.